Investment Banking
An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.
Complete the form below to download your copy of the report
Stay up-to-date with the latest William Blair news and insights
With thoughtful planning and strategic management of their portfolios, investors can successfully balance their retirement and wealth-transfer goals.
Read moreUnderstanding the nuances between retirement plans can be challenging. William Blair’s Quick Reference Guide to Retirement Plans compares and contrasts features such as account establishment, account contributions, and accessibility.
Read moreWhile the Blair Connect summer internship program is only two years old, it’s already impacting how we approach recruiting, says Drew Buckley, CFA, partner, and research analyst on the global equity team.
Watch the videoInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
